Literature DB >> 6299950

Temperature-sensitive mutant of coxsackievirus B3 establishes resistance in neonatal mice that protects them during adolescence against coxsackievirus B3-induced myocarditis.

C J Gauntt, R E Paque, M D Trousdale, R J Gudvangen, D T Barr, G J Lipotich, T J Nealon, P S Duffey.   

Abstract

Inoculation of neonatal CD-1 mice by multiple routes with an amyocarditic temperature-sensitive (ts) mutant (ts 1) derived from a myocarditic parent variant of coxsackievirus B3 (CVB3(m)) resulted in approximately half of the neonates surviving to adolescence. Challenge of the ts 1 survivors with CVB3(m) did not induce myocarditis, as assessed by histological examination of heart tissues. Virus was not detected in heart tissues of adolescent ts 1 survivors, but inoculation of these mice with CVB3(m) resulted in virus concentrations similar in titers to those found in CVB3(m)-inoculated normal adolescent mice. The ts 1 survivors did not contain detectable levels of anti-CVB3(m) neutralizing antibody, but upon challenge with CVB3(m) they produced antibody more rapidly and to higher titers than did normal CD-1 adolescents after primary inoculation with CVB3(m). Cell-mediated immunity in ts 1 survivors was compared with that of normal mice after challenge with CVB3(m). The capacity for production of migration inhibitory factor was assessed by the agarose droplet cell migration inhibition assay, using peritoneal exudate cells and a CVB3(m) cell lysate or KCl-extracted antigens from heart tissues of CVB3(m)-inoculated mice. Migration inhibitory factor activity was not detected in cultures of splenic leukocytes from ts 1 survivors of CVB3(m)-inoculated ts 1 survivors, but it was readily detected in cultures of splenic leukocytes from CVB3(m)-inoculated normal adolescent mice. The [(3)H]thymidine stimulation assay, performed with splenic lymphoid cells and purified CVB3(m) particles, revealed that lymphocytes from normal mice, whether inoculated with CVB3(m) or not, were not stimulated by CVB3(m) particle antigens, whereas lymphoid cells from a significantly higher proportion of ts 1 survivors, whether inoculated with CVB3(m) or not, responded with a stimulation index >/=2.0. The cells responding with positive stimulation were T lymphocytes. A higher proportion of normal mice and ts 1 survivors, both inoculated with CVB3(m), contained splenic cytotoxic T lymphocytes with higher reactivity against CVB3(m)-infected neonatal skin fibroblasts than against normal skin fibroblasts, as assessed by a (51)Cr release assay. The group of uninoculated ts 1 survivors present as a high proportion of individuals with cytotoxic T-lymphocyte reactivity against both uninoculated and CVB3(m)-inoculated skin fibroblasts. However, ts 1 survivors and normal mice possessed the same proportions of splenic lymphocytes carrying either allele for Lyt 1 and Lyt 2 surface markers. The results suggest two mechanisms by which ts 1 survivors exhibit resistance to CVB3(m) induction of myocarditis, namely, the rapid production of high-titered anti-CVB3(m) neutralizing antibody in response to CVB3(m) inoculation and altered cell-mediated immune responses against CVB3(m)-induced viral or novel cellular antigens. The data are compatible with the notion that an immune deviation mechanism, thought to be controlled through a mechanism requiring suppressor cell activity which inhibits macrophage activation in ts 1 survivors, protects these mice from induction of myocarditis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6299950      PMCID: PMC348027          DOI: 10.1128/iai.39.2.851-864.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  Thymus cell migration: 3HTdR-labeled and theta-positive cells in peripheral lymphoid tissues of newborn mice.

Authors:  A D Chanana; D D Joel; J Schaedeli; M W Hess; H Cottier
Journal:  Adv Exp Med Biol       Date:  1973       Impact factor: 2.622

Review 2.  Studies on the development of immunity: the response to sheep red blood cells.

Authors:  R Auerbach
Journal:  Curr Top Dev Biol       Date:  1972       Impact factor: 4.897

3.  Enumeration and analysis of antibody-forming cell precursors in the neonatal mouse.

Authors:  J L Press; N R Klinman
Journal:  J Immunol       Date:  1973-09       Impact factor: 5.422

4.  Synthesis of ribonucleic acids in KB cells infected with rhinovirus type 14.

Authors:  C J Gauntt
Journal:  J Gen Virol       Date:  1973-11       Impact factor: 3.891

5.  Tumor-specific antigen solubilized by hypertonic potassium chloride.

Authors:  M S Meltzer; E J Leonard; H J Rapp; T Borsos
Journal:  J Natl Cancer Inst       Date:  1971-09       Impact factor: 13.506

6.  Separation of functional subsets of human T cells by a monoclonal antibody.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

Review 7.  Viral myocarditis. A review.

Authors:  J F Woodruff
Journal:  Am J Pathol       Date:  1980-11       Impact factor: 4.307

8.  Studies of generation of B-cell diversity in mouse, man, and chicken.

Authors:  M D Cooper; J F Kearney; P M Lydyard; C E Grossi; A R Lawton
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1977

9.  Biological and chemical characterization of human histocompatibility antigens.

Authors:  R A Reisfeld; B D Kahan
Journal:  Fed Proc       Date:  1970 Nov-Dec

10.  Experimental Coxsackie virus B-3 and B-4 myocarditis in mice.

Authors:  C Kawai; A Matsumori; N Kumagai; M Tokuda
Journal:  Jpn Circ J       Date:  1978-01
View more
  10 in total

1.  In situ immune autoradiographic identification of cells in heart tissues of mice with coxsackievirus B3-induced myocarditis.

Authors:  E K Godeny; C J Gauntt
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

Review 2.  Role of natural killer cells in experimental murine myocarditis.

Authors:  C J Gauntt; E K Godeny; C W Lutton; G Fernandes
Journal:  Springer Semin Immunopathol       Date:  1989

3.  Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain.

Authors:  H Zhang; P Morgan-Capner; N Latif; Y A Pandolfino; W Fan; M J Dunn; L C Archard
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

4.  Antimyocarditic activity of the guanine derivative BIOLF-70 in a coxsackievirus B3 murine model.

Authors:  C J Gauntt; H M Arizpe; J T Kung; K K Ogilvie; U O Cheriyan
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

5.  Coxsackievirus B3 infection alters plasma membrane of neonatal skin fibroblasts.

Authors:  C W Lutton; C J Gauntt
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

6.  Secondary enterovirus infection in the murine model of myocarditis. Pathologic and immunologic aspects.

Authors:  M A Beck; N M Chapman; B M McManus; J C Mullican; S Tracy
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

7.  Deletions within the 5'UTR of coxsackievirus B3: consequences for virus translation and replication.

Authors:  Isabelle P Hunziker; Christopher T Cornell; J Lindsay Whitton
Journal:  Virology       Date:  2006-11-03       Impact factor: 3.616

8.  Cardiomyopathy and myocarditis--a review of new aspects in research in West Germany.

Authors:  B Maisch; T Izumi
Journal:  Heart Vessels Suppl       Date:  1985

9.  Levamisole exacerbates coxsackievirus B3-induced murine myocarditis.

Authors:  R J Gudvangen; P S Duffey; R E Paque; C J Gauntt
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

10.  Ribosomal Initiation Complex Assembly within the Wild-Strain of Coxsackievirus B3 and Live-Attenuated Sabin3-like IRESes during the Initiation of Translation.

Authors:  Amira Souii; Manel Ben M'hadheb-Gharbi; Bruno Sargueil; Audrey Brossard; Nathalie Chamond; Mahjoub Aouni; Jawhar Gharbi
Journal:  Int J Mol Sci       Date:  2013-02-25       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.